Abstract 3218: High pathological CR rate and low recurrence rate was observed in liver metastasis of colorectal cancer after preoperative bevacizumab plus FOLFOX therapy

Abstract

Abstract [Background] We reported the effectiveness of intraoperative contrast-enhanced ultrasonography using perflubutane (SONAZOIDTM) for complete resection of liver metastasis from colorectal cancer (CRC) after Bevacizumab (Bmab)+FOLFOX therapy (Annual meeting of AACR, 2010). In this study, we report pathological CR (pCR) rate of resected liver tumors and recurrence rate of disappeared lesions that were not resected. [Material and methods] Sixteen patients of advanced CRC with liver metastasis only (no extrahepatic lesion) were treated with Bmab+FOLFOX therapy. Response rate of chemotherapy was 81%. Among the 16 patients, 8 (50%) were underwent liver resection after chemotherapy. We study 6 of the 8 patients, who were followed up longer than a year (20-33 months). [Result] By CT angiography, 47 liver metastases were detected before chemotherapy. By intraoperative contrast-enhanced ultrasonography, 26 liver tumors were detected and resected. In histological examination, 11 (42%) were without viable cancer cell (pCR). Among 21 lesions that were not detected by intraoperative ultrasound and not resected, only 2 lesions were re-detected in follow up period and both lesion were resected. [Conclusion] High pCR rate and low recurrence rate was observed in liver metastasis of colorectal cancer after preoperative Bmab + FOLFOX therapy. Contrast-enhanced ultrasonography was effective for complete resection of liver metastases, as well as low recurrence rate of disappeared lesion after chemotherapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3218. doi:10.1158/1538-7445.AM2011-3218